← Human Trials & Peer-Reviewed Studies
Recurarization with magnesium sulfate administered after two minutes sugammadex reversal: A randomized, double-blind, controlled trial.
Plain-language guide to PMID 37393856 (2023): double-blind randomized controlled trial of Vitamin D, K2, Magnesium and Zinc in 60 patients.
Key Facts
- PMID
- 37393856
- Journal
- Journal of clinical anesthesia
- Year
- 2023
- Study type
- Randomized Controlled Trial
- Authors
- Germano-Filho PA et al. (6 authors)
- DOI
- 10.1016/j.jclinane.2023.111186
What This Study Did, in Plain Language
What Was Tested
This randomized controlled trial looks at Vitamin D, K2, Magnesium and Zinc.
The current study tested the hypothesis that magnesium sulfate after reversal with sugammadex causes recurarization.
Who Took Part
According to the abstract, 60 patients were involved.
Included 60 patients undergoing for elective otolaryngological surgery.
The primary outcome was the number of patients who exhibited recurarization (normalized train-of-four ratio < 0.9).
How the Study Was Run
The design is described as randomized, double-blind and placebo-controlled.
The patients were allocated by chance, so the Vitamin D, K2, Magnesium and Zinc group and the comparison group should start out alike.
As a double-blind Vitamin D, K2, Magnesium and Zinc study, the assignments were hidden from both participants and investigators until the end.
A placebo (an inactive look-alike) gave the Vitamin D, K2, Magnesium and Zinc group a baseline to be compared against.
A single-center, prospective, randomized, double-blind, controlled trial.
Terciary care hospital in Rio de Janeiro, Brazil.
Neuromuscular function was measured by acceleromyography.
What Was Measured
The subject headings attached to it are Sugammadex, Rocuronium, gamma-Cyclodextrins, Magnesium Sulfate, Neuromuscular Nondepolarizing Agents, Androstanols and Brazil.
Author keywords: Neuromuscular blockade, Neuromuscular blocking agents and Postoperative residual curarization.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of Vitamin D, K2, Magnesium and Zinc in 60 patients.
Its findings take up roughly 5 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.
The publication is from 2023 (Journal of clinical anesthesia), a journal based in United States.
More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.
Our Notes on the Compound
Vitamin D, K2, Magnesium and Zinc: Magnesium is described as required for AMPK to function.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.